Mepolizumab (Nucala) in The Treatment of Severe Eosinophilic Asthma

StraussArticles
Written By Rachele Wright

We report our real-world results of using mepolizumab in patients with severe eosinophilic asthma in an office environment. This was a retrospective study; written permission was granted by all patients to use results of their treatment with mepolizumab, a monoclonal antibody directed against the interleukin-5 (IL-5) cytokine.

Dr. Strauss, Nesreen Jawhari, MN and The Cleveland Allergy and Asthma Center published this paper in the Annals of Allergy, Asthma & Immunology.

The full article also available here in PDF format.

Rachele Wright http://www.wrightoutcomes.net
Previous

A New Look at an Old Drug - Terbutaline
Next

The use of a tapering dose of methylprednisolone for asthma exacerbations: Is it adequate?